Beyond prostate-specific antigen: Alternate serum markers

M. L. Ramírez, E. C. Nelson, Christopher P Evans

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

There is a need to improve existing methods for early diagnosis of prostate cancer (CaP) and to identify men at risk for developing aggressive disease. In an effort to replace and/or supplement prostate-specific antigen many serum analytes have been examined, but with little supportive data for clinical use. Recently, technological advances in molecular assays have improved investigational outcomes and have led to the discovery of a number of prospective markers with high specificity. Further promise for providing more accurate CaP diagnosis and prognosis lies in proteomic array profiling and DNA methylation assays. This review illustrates the current benefits and limitations of potentially useful CaP serum markers that have considerable existing data and touches upon other future markers as well as the field of proteomics.

Original languageEnglish (US)
Pages (from-to)216-229
Number of pages14
JournalProstate Cancer and Prostatic Diseases
Volume11
Issue number3
DOIs
StatePublished - 2008

Fingerprint

Prostate-Specific Antigen
Proteomics
Biomarkers
DNA Methylation
Early Detection of Cancer
Prostatic Neoplasms
Serum

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Beyond prostate-specific antigen : Alternate serum markers. / Ramírez, M. L.; Nelson, E. C.; Evans, Christopher P.

In: Prostate Cancer and Prostatic Diseases, Vol. 11, No. 3, 2008, p. 216-229.

Research output: Contribution to journalArticle

@article{87393d5ccf7f44e187111cae0a32f1a9,
title = "Beyond prostate-specific antigen: Alternate serum markers",
abstract = "There is a need to improve existing methods for early diagnosis of prostate cancer (CaP) and to identify men at risk for developing aggressive disease. In an effort to replace and/or supplement prostate-specific antigen many serum analytes have been examined, but with little supportive data for clinical use. Recently, technological advances in molecular assays have improved investigational outcomes and have led to the discovery of a number of prospective markers with high specificity. Further promise for providing more accurate CaP diagnosis and prognosis lies in proteomic array profiling and DNA methylation assays. This review illustrates the current benefits and limitations of potentially useful CaP serum markers that have considerable existing data and touches upon other future markers as well as the field of proteomics.",
author = "Ram{\'i}rez, {M. L.} and Nelson, {E. C.} and Evans, {Christopher P}",
year = "2008",
doi = "10.1038/pcan.2008.2",
language = "English (US)",
volume = "11",
pages = "216--229",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Beyond prostate-specific antigen

T2 - Alternate serum markers

AU - Ramírez, M. L.

AU - Nelson, E. C.

AU - Evans, Christopher P

PY - 2008

Y1 - 2008

N2 - There is a need to improve existing methods for early diagnosis of prostate cancer (CaP) and to identify men at risk for developing aggressive disease. In an effort to replace and/or supplement prostate-specific antigen many serum analytes have been examined, but with little supportive data for clinical use. Recently, technological advances in molecular assays have improved investigational outcomes and have led to the discovery of a number of prospective markers with high specificity. Further promise for providing more accurate CaP diagnosis and prognosis lies in proteomic array profiling and DNA methylation assays. This review illustrates the current benefits and limitations of potentially useful CaP serum markers that have considerable existing data and touches upon other future markers as well as the field of proteomics.

AB - There is a need to improve existing methods for early diagnosis of prostate cancer (CaP) and to identify men at risk for developing aggressive disease. In an effort to replace and/or supplement prostate-specific antigen many serum analytes have been examined, but with little supportive data for clinical use. Recently, technological advances in molecular assays have improved investigational outcomes and have led to the discovery of a number of prospective markers with high specificity. Further promise for providing more accurate CaP diagnosis and prognosis lies in proteomic array profiling and DNA methylation assays. This review illustrates the current benefits and limitations of potentially useful CaP serum markers that have considerable existing data and touches upon other future markers as well as the field of proteomics.

UR - http://www.scopus.com/inward/record.url?scp=50649102772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50649102772&partnerID=8YFLogxK

U2 - 10.1038/pcan.2008.2

DO - 10.1038/pcan.2008.2

M3 - Article

C2 - 18227856

AN - SCOPUS:50649102772

VL - 11

SP - 216

EP - 229

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 3

ER -